RP
EDIT icon

Raelipskie Partnership’s Editas Medicine EDIT Stock Holding History

Raelipskie Partnership’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$410 – 122
2025
Q4 		$410 Hold
200
– – ﹤0.01% 113
2025
Q3 		$694 Hold
200
– – ﹤0.01% 111
2025
Q2 		$440 Hold
200
– – ﹤0.01% 113
2025
Q1 		$232 Hold
200
– – ﹤0.01% 119
2024
Q4 		$254 Hold
200
– – ﹤0.01% 117
2024
Q3 		$682 Buy
+200
New +$871 ﹤0.01% 119

Other funds holding EDIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Raelipskie Partnership's EDIT Position: Q1 2026 in Review

Raelipskie Partnership sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 200 shares — an estimated $410 sold.

Raelipskie Partnership first reported a position in EDIT in Q3 2024 and held it in 6 quarters. The position peaked at $694 in Q3 2025. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Raelipskie Partnership reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
  • Raelipskie Partnership sold 200 Editas Medicine shares in Q1 2026, an estimated $410.
  • Raelipskie Partnership first reported a position in Editas Medicine in Q3 2024 and held it in 6 quarters.
  • Raelipskie Partnership's Editas Medicine position peaked at $694 in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Raelipskie Partnership's 13F filing for Q1 2026, filed 29 Apr 2026.